Birth Defect Class Action Lawsuit To Move Forward in Australia
An Australian court has cleared the way for a class action lawsuit to move forward against the makers of thalidomide, a morning sickness drug given to pregnant women more than fifty years ago, which was later linked to a risk of birth defects.
The thalidomide birth defect class action lawsuit seeks to represent every Australian born between January 1, 1958 and December 31, 1970, who developed a birth defect after their mother took thalidomide during pregnancy.
The case was cleared to proceed earlier this month by a Victoria state supreme court, which dismissed objections by the manufacturer, Grunenthal. Diageo Scotland Ltd. and Distillers Company Ltd. are also defendants in the lawsuit.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Grunenthal wanted the case moved to Germany, where it is headquartered, but the Victoria Supreme Court determined that the inconvenience for the company was overshadowed by the inconvenience of the plaintiffs in the case.
The lawsuit is seeking compensation for victims’ pain and suffering, lost wages and future medical treatment.
Thalidomide was sold in Australia between 1957 and 1961 and was marketed as a safe and non-toxic treatment. However, it was later linked to birth deformities in the newborns of the mothers taking the drug, which was sold worldwide.
The lead plaintiff, Lynette Rowe, was born without arms and legs after her mother took the drug to combat morning sickness.
The companies involved have reached a number of out-of-court settlements with children of mothers who took the drug, but there has never been a court ruling on their liability. An attempt to make Grunenthal executives face criminal charges fell through in the 1970s.
"*" indicates required fields
More Top Stories
A new report indicates the U.S. Navy is struggling to process tens of thousands of Camp Lejeune water poisoning claims due to a lack of resources.
A group of plaintiffs have filed a motion with the U.S. JPML seeking consolidation of all Bard implanted port lawsuits before one judge for pretrial proceedings.
A Tepezza hearing loss lawsuit accuses the manufacturer of failing to provide adequate warning about the risks of the thyroid eye disease drug.